Press Releases

BRISBANE, CA and ST. LOUIS, MO, April 27, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced 105 million in Series C Financing, and and proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies.

BRISBANE, CA and ST. LOUIS, MO, April 10, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, will present new preclinical T-ALL data on highly-differentiated Anti-CD47 antibody AO-176 at AACR 2021.

BRISBANE, CA and ST. LOUIS, MO, April 7, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member.

BRISBANE, CA and ST. LOUIS, MO, February 16, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the company’s participation at upcoming healthcare investor conferences.

BRISBANE, CA and ST. LOUIS, MO, February 16, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the company’s participation at upcoming healthcare investor conferences.

BRISBANE, CA and ST. LOUIS, MO, February 9, 2021 – Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors. With Encouraging Safety and Anti-tumor Activity for AO-176 Monotherapy in Phase 1 Trial, Advancing AO-176 in Combination with Anti-PD-1.

BRISBANE, CA and ST. LOUIS, MO, January 6, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that Julie Hambleton, M.D., the Company’s Interim President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference.

BRISBANE, CA and ST. LOUIS, MO, December 7, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company announces first dedicated clinical trial of an Anti-CD47 Antibody in Multiple Myeloma at ASH 2020, new preclinical data presented on AO-176 in Multiple Myeloma

BRISBANE, CA and ST. LOUIS, MO, December 6, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020

BRISBANE, CA and ST. LOUIS, MO, November 16, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, appoints Ronald Krasnow, Esq. as Chief Operating Officer.

BRISBANE, CA and ST. LOUIS, MO, November 9, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020.

BRISBANE, CA and ST. LOUIS, MO, October 26, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced upcoming presentations at conferences and medical meetings.

BRISBANE, CA and ST. LOUIS, MO, October 5, 2020 – Arch Oncology Advances Anti-CD47 Antibody AO-176 into
Chemotherapy Combination Phase 1/2 Trial in Solid Tumors. Citing Encouraging Safety and Anti-tumor Activity for
AO-176 Monotherapy in Phase 1 Trial, They are Expanding into Chemotherapy Combination Phase 1/2 Trial.

BRISBANE, CA and ST. LOUIS, MO, June 22, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced today the formation of a Scientific Advisory Board (SAB) and appointment of five leading oncology experts.

BRISBANE, CA and ST. LOUIS, MO, April 21, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton to the Company’s Board of Directors.

BRISBANE, CA and ST. LOUIS, MO, August 12, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Drew Dennison to Board of Directors.

BRISBANE, CA and ST. LOUIS, MO, May 22, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Kirk Christoffersen as Chief Business Officer. In this newly-created position, Mr. Christoffersen will lead Arch Oncology’s corporate strategy and other business functions reporting to Julie Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology.

BRISBANE, CA and ST. LOUIS, MO, March 29, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 therapies for cancer, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, GA.

BRISBANE, CA and ST. LOUIS, MO, March 25, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing. The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.

BRISBANE, CA and ST. LOUIS, MO, February 6, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of next-generation anti-CD47 antibody therapies for cancer, today announced the initiation of a new Phase 1 clinical trial of AO-176 in select solid tumors with the first patient dosed.